The use of bariatric surgery for the treatment of morbid obesity has increased annually for the last decade. Although many studies have demonstrated the efficacy and durability of bariatric surgery for weight loss, there are limited data regarding long-term side effects of these procedures. Recently, there has been an increased focus on the impact of bariatric surgery on bone metabolism. Bariatric surgery utilizes one or more of three mechanisms of action resulting in sustained weight loss. These include restriction (gastric banding, vertical banded gastroplasty and sleeve gastrectomy), malabsorption surgery with or without associated restriction (Roux en Y gastric bypass, duodenal switch, biliopancreatic diversion and jejunoileal bypass) and changes in gut-derived hormones that control energy metabolism also referred to as neuro-hormonal control of energy metabolism (Roux en Y gastric bypass, duodenal switch, biliopancreatic diversion, jejunoileal bypass, surgical procedures as above and gastric sleeve). Weight reduction has been associated with increased bone resorption but the mechanisms behind this have not yet been fully elucidated. Each of the mechanisms of action of bariatric surgery (restriction, malabsorption, neuro-hormonal control of energy metabolism) may uniquely affect bone resorption. In this paper we will review the current state of knowledge regarding the relationship between bariatric surgery and bone metabolism with emphasis on possible mechanisms of action such as malnutrition, hormonal interactions and mechanical unloading of the skeleton. Further, we suggest a future research agenda.
INTRODUCTION
Obesity is a global epidemic with more than 300 million individuals affected worldwide. 1, 2 Serious comorbidities often accompany obesity (e.g., type 2 diabetes, hypertension, dyslipidemia, gallstones, cancer, sleep apnea, fatty liver and psychiatric disorders). Accordingly, life expectancy may be significantly reduced and the quality of life may be substantially impaired. 3 Early and aggressive diet, exercise and behavioral intervention can produce a modest 10-15% short-term reduction in weight and may partially or completely reverse the metabolic comorbidities associated with obesity. 4 However, compliance is difficult and weight loss is only rarely maintained over the long term. 5 An important role for operative therapy was officially endorsed over two decades ago by a Consensus Panel of the National Institutes of Health. 6 Since then, interest in bariatric surgery has skyrocketed. The prevalence of bariatric surgery in the United States has increased nearly sixfold from 1998 to 2002. 7 Over time, a variety of operative techniques has evolved with most bariatric procedures now being performed laparoscopically. They can be divided into two general categories: restrictive procedures (i.e., adjustable gastric banding and sleeve gastrectomy) and malabsorptive procedures with or without restrictive components (i.e., biliopancreatic diversion, duodenal switch and Roux-Y-gastric bypass.
8 ) The efficacy and safety profiles among these categories vary substantially as a result of differences in the anatomic configurations produced and the alterations in gastrointestinal physiology that are created by the different surgical procedures. Whichever method is used, numerous short-and medium-term studies have confirmed that bariatric surgery is superior to conventional, non-operative methods in inducing weight loss and resolving comorbidities. [9] [10] [11] Although long-term data are more limited, it generally supports the durability of operative methods. In a recent 4-year randomized comparison of laparoscopic Roux-en-Y-gastric bypass (LRYGB) and laparoscopicadjusted gastric band, excess weight loss was noted to be 68.4% and 45.4% respectively. 2, 12 Nearly identical results have been documented in another large study that examined a 5-10-year experience. 13 However, these encouraging reports must be balanced by the recognition that major complications can occur in both short-and long-term settings. The US Bariatric Outcomes Longitudinal Database reported 1-year complication rates of 4.6%, 10.8%, 14.9% and 25.7%, respectively, following aparoscopicadjusted gastric band placement, sleeve gastrectomy, LRYGB and biliopancreatic diversion. 14 In the longer term, nearly 10% of all LRYGB patients will experience serious complications and nearly one-half of all aparoscopic-adjusted gastric band procedures will fail. The contribution of nutritional factors is of paramount importance in the long-term. There is also growing evidence that all bariatric procedures are capable of producing significant nutritional and metabolic abnormalities. 15, 16 In particular, bone mineral metabolism is often adversely affected although the extent of these abnormalities and their underlying pathophysiology are incompletely understood. [16] [17] [18] In addition, the extent of bone loss varies with each study and none have been carried out in a sufficient number of patients to allow a firm conclusion. [19] [20] [21] Thus, the aim of this review is to summarize the current state of knowledge regarding the relationship between bariatric operations and bone metabolism, to understand the specific mechanisms of action and to suggest further research studies.
LITERATURE SEARCH METHODS
We searched MEDLINE on Pubmed using the following search terms:
'Incidence and prevalence of bariatric surgery' 'Bariatric surgery and bone diseases' 'Bariatric surgery and hormones'
The references were included/excluded from each search for the following reasons: (1) studies shorter than 1 week, (2) failure to repeat outcome data and (3) inadequate sample size.
Regarding 'Incidence and prevalence of bariatric surgery' 2059 references were generated; we chose 18 references among them. We selected 24 references among the references generated in the subgroup 'bariatric surgery and bone diseases' and 65 references among the references selected for 'bariatric surgery and hormones'. When previous systematic reviews were used, we independently examined the individual studies to confirm or extend previous review findings.
BONE REMODELING AND ITS RELATIONSHIP TO BONE MINERAL DENSITY
The skeleton has two well-established functions. It provides the structural framework to support the muscles and therefore allow movement, and it acts as a reservoir for minerals. The physiological maintenance of the skeletal system is achieved by bone remodeling. This is the process by which bone is renewed to maintain bone strength and mineral homeostasis, and it is characterized by the localized removal of old bone and replacement with newly formed bone. 22 The fundamental unit of bone remodeling is the 'bone-multicellular unit', which consists of a tightly regulated process of bone resorption followed by formation. Two cell types are fundamental to this process: osteoblasts (formation) and osteoclasts (resorption). 23 Normally, the processes of resorption and formation are tightly coupled through a complex network of endocrine and paracrine signals. Primary among these is the full control of osteoclastogenesis through receptor activator of nuclear factor kappa-B ligand (RANK-L)/osteoprotegerin by osteoblasts. (see Figure 1) . Second, the osteocytes produce FGF23 that inhibits phosphorus reabsorption, that is, induces PO4 loss and 1,25 (OH)2D3 production in the renal proximal tubule. 24 When the rates of resorption and formation are balanced, total bone mass remains constant. Whenever osteoclastic function uncouples from osteoblastic function, either temporally or spatially, a net gain or loss of bone mass may occur. All factors leading to the net loss or gain of bone do so by disrupting the balance between osteoclastic and osteoblastic function. The numerous regulatory mechanisms involved in the control of bone remodeling have been reviewed elsewhere and are beyond the scope of this report. Figure 1 . Schema of mechanisms of bone loss after bariatric surgery. Proposed mechanisms of bone loss after bariatric surgery fall into four categories: Mechanical unloading, nutritional effects, gut and adipose tissue effects. All pathways ultimately impact bone loss by either reducing osteoblast (formation) function or increasing osteoclast (resorption) function. Mechanical unloading of the skeleton is mediated by osteocytes that act as mechanostats responding to the reduction in bone deformation with weight loss by secreting sclerostin, which in turn negatively regulates Wnt-canonical signaling, a key factor in osteoblast differentiation. Nutritional effects result largely from reduced absorption of key osteogenic components such as calcium and vitamin D. Calcium and vitamin D each have direct effects on bone remodeling but result in secondary hyperparathyroidism which also impacts bone remodeling. The reduction of adipose tissue results in changes of adipokines (leptin and adiponectin) secretion and a decrease of estradiol levels due to a decrease in aromatization of testosterone. In addition, the removal of duodenum was shown to change gut-derived hormones secretion, in particular it causes a decrease in ghrelin and GIP secretion along with an increase in GLP-1 and serotonin secretion (red arrows indicate inhibition of resorption/formation, green arrows indicate stimulation of resorption/formation).
IMPACT OF BARIATRIC SURGERY ON BONE METABOLISM
Bariatric surgery is commonly associated with a decrease in bone mass, [26] [27] [28] and also appears to be associated with an increase in fracture risk. 29, 30 Until recently, the impact of major weight loss on bone metabolism was thought to result solely from a combination of mechanical and nutritional effects. However, recent insights into the convergence of bone and energy metabolism have demonstrated that a third mechanism involving neuro-hormonal regulation of bone turnover may also have a significant role. 31 Specifically, changes in adipose and gut hormones associated with bariatric surgery appear likely to significantly affect bone metabolism in the postoperative period.
32 Figure 1 present a schema of mechanisms by which bariatric surgery may impact bone metabolism.
Mechanical effects on bone Mechanical loading of bone has a key role in determining bone mass, strength and size. 33, 34 It is generally accepted that bone remodeling serves the dual purpose of promoting repair of microdamage and adapting to mechanical stresses. As early as 1892, Wolff reported that orientation of bone trabeculae in bone coincides with known stresses on the bone. He postulated that bone mechanical loading resulted in remodeling that strengthened the bone as needed. This concept has come to be known as 'Wolff's Law'. 35 Frost 36 proposed a mechanism explaining Wolff's observations by which mechanical loading results in the deformation of the bone, localized remodeling. Subsequent studies have demonstrated that the cellular mechanism of this environmental response is via the osteocyte, a cell buried in the bone matrix that acts as a 'mechanostat' to sense deformation of bone in response to mechanical loading. The details of the transmission of this loading signal are slowly being elucidated and have been shown to be dependent on the protein sclerostin, a product of the SOST gene. 37 Clinically, several lines of evidence demonstrate the relationship between mechanical loading and bone mineral density (BND). In this regard, weight bearing exercise has been shown to significantly increase BND and reduce fracture risk in postmenopausal women, 14 as well as in patients on a nonsurgical weight loss program. 38 In contrast, bone loss has been demonstrated in various conditions resulting in immobilization and unloading of the skeleton including spinal cord injury, 39 bed rest, 40 space flight, 41 and in animal studies, hindlimb unloading. 42 Mechanical loading sensed by osteocytes inhibits the production of mRNA for the SOST gene, which in turn results in decreased sclerostin production. In contrast, when the skeleton is unloaded sclerostin production increases and then negatively regulates canonical-Wnt signaling, an important pathway for osteoblast differentiation and function. 43 Mechanical unloading therefore results in a net loss of bone mass by reducing osteoblast function and in turn bone formation. Studies in SOST-deficient mice demonstrate that sclerostin is necessary for bone loss upon unloading of the skeleton. 44 Taken together, these data indicate that sclerostin may be a useful way to monitor the activity of the mechanostat function in osteocytes and, therefore, might be useful for delineating the extent to which mechanical loading has a role in bone loss after bariatric surgery. Further, sclerostin is an attractive target for pharmaceutical manipulation directed as preventing bone loss after bariatric surgery.
Although it is likely that mechanical unloading has at least a partial role in explaining the loss of bone after bariatric surgery, there is currently no data comparing BND and fracture risk of a population at a given weight, with the BND and fracture risk of a population who achieve the same weight after bariatric surgery.
Nutritional effects on bone Normal bone metabolism is dependent on an adequate dietary calcium and phosphorus intake, and is regulated by the integrated action of parathyroid hormone, vitamin D and FGF23 on calcium transport mechanisms in the gut, kidney and bones. Biochemical analyses of calcium, phosphorus, 25(OH)-vitamin D and parathyroid hormone are often used to monitor mineral homeostasis in the preoperative and postoperative periods. In addition, serial measurements of BND and bone mineral content (BMC) by dualenergy X-ray absorptiometry can be used to quantitate changes in bone mass. When reported in the literature, these laboratory and morphometric values are often imprecise and inconsistent and, at times, they even appear contradictory. These discrepancies may be accounted for by the usually small and heterogenous sample sizes, variable dietary protocols and, in the case of dual-energy X-ray absorptiometry, a relative insensitivity in the presence of morbid obesity. 45 Even with the above limitations, several clinical patterns can be discerned. Obese individuals in general often have abnormally low 25(OH)-vitamin D levels, a phenomenon that is thought to occur as a result of sequestration of vitamin D in the excess adipose tissue or from inadequate sunlight exposure related to both a more sedentary lifestyle and a tendency to 'cover up' due to modesty. 46 Patients who undergo bariatric surgery, frequently develop abnormalities of both calcium homeostasis and bone metabolism with the magnitude of the changes being directly proportional to the amount of weight lost. 47 Abnormalities of vitamin D and parathyroid hormone are particularly variable, depending on the type of procedure performed. The serum calcium level usually remains normal in the postoperative period because of its tight physiological regulation; relative hypocalcemia occurs only rarely. Importantly, all of the adverse effects on bone metabolism following bariatric surgery can be partially or completely reversed by regular and aggressive dietary supplementation. 48 Malabsorptive bariatric procedures. Because calcium is preferentially and actively absorbed in the proximal foregut and vitamin D requires bile acids and pancreatic secretions for optimal absorption, operations that bypass the duodenum and proximal jejunum (e.g., RYGB and biliopancreatic diversion) can cause malabsorption of both of these key osteogenic nutrients. 49, 50 Calcium malabsorption alone results in a lack of adequate substrate for bone mineralization. Vitamin D insufficiency can further aggravate this effect because of its diminished action on the bowel and kidney, 51 and because it can cause secondary hyperparathyroidism. 52 There is also recent and growing evidence that vitamin D has direct effects on bone cells through its interaction with specific vitamin D receptors. [53] [54] [55] [56] [57] These actions are not completely characterized but appear to include anabolic effects on osteoblast differentiation, proliferation and mineralization, as well as stimulatory effects on osteoclast precursors to enhance cellular adhesion. Taken together, these effects act to significantly increase bone turnover as measured by such markers as serum osteocalcin and bone-specific alkaline phosphatase and urinary N-telopeptide of type I collagen. As a result, BMC and BMD are significantly decreased especially in the hip including both the trochanter and the femoral neck. 58, 59 Restrictive bariatric procedures. By limiting the total amount of food consumed, restrictive bariatric surgery reduces the total amount of nutrients the body receives. Depending on the individual patient and the specific dietary history, this restriction may have a significant negative impact on bone metabolism even though serum calcium, vitamin D and parathyroid hormone do not usually change. 60, 61 Again, increases in bone turnover can be documented by the characteristic increases in serum and urinary bone markers. Moreover, BMC and BMD are generally decreased. 60 
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The RYGB and the gastric sleeve procedure both reduce the total amount of acid produced by the stomach. This alkalinization of gastric juice may, in turn, impede the fractional absorption of calcium as well as other nutrients that depend on a lower pH. 62 The numerous effects of dietary and surgical weight loss on bone metabolism are summarized in Table 1 .
Neuro-hormonal effect on bone The last decade has witnessed an explosion of knowledge concerning the mechanisms by which the gut communicates with bone. The convergence of bone and energy metabolism has been the focus of a series of elegant gene knockout studies in the mouse. 63 Among the numerous hormones originating from the gut, the adipokines leptin and adiponectin have relatively well-recognized effects on bone metabolism, although less abundant but growing evidence exists for serotonin, glucagonlike peptide-1 (GLP-1), ghrelin, peptide YY (PYY), glucosedependent insulinotropic polypeptide (GIP) and glucagon-like peptides (GLP-1, GLP-2). In addition, visceral and somatic fat affects bone metabolism indirectly via modulation of gonadal hormone levels 64, 65 (see Table 2 ).
Leptin
Leptin, is released systemically by the adipocytes in amounts that are proportional to total body fat, 66 thus reflecting whole body energy stores. It is believed to inform the brain about systemic fat, that is, energy stores. In addition, leptin affects bone metabolism through at least two separate central nervous system mechanisms. The first is mediated by the brain-derived serotonin (BDS) that, through modulation of the sympathetic nervous system tone, activates cell surface b-adrenergic receptors in osteoblasts, upregulates this cells function and induces bone formation. 63, 67 The second mechanism is mediated by the cocaine-amphetamine regulated transcript (CART). Leptin increases CART that, via undetermined mechanism(s), regulates RANK-L expression in osteoblasts. RANK-L in turn regulates osteoclast function and results in increased bone resorption. 31 Leptin levels decrease significantly after bariatric surgery in proportion to loss of total body fat. 68 Furthermore, a decrease in leptin after bariatric surgery was inversely correlated with increased levels of markers of bone formation and resorption. The increment in markers of resorption, however, significantly exceeded that of markers of formation indicating a tipping of the balance toward bone loss. 69 This seems to suggest that leptin may have a net positive impact on BND. An alternative possibility is that the increased leptin levels may be one of the causes of increased bone mass in obese subjects. Therefore, the decline of leptin levels after bariatric surgery may result in transiently increased bone resorption and decreased formation. 69 Adiponectin Adiponectin also derives from fat tissue and it exerts numerous biological functions including modulation of insulin sensitivity, 70 protection against hypertension 71 and suppression of atherosclerosis, 72 liver fibrosis 73 and tumor growth. 74 Oshima et al.
75
reported that adiponectin reduces in vitro differentiation of progenitor cells to osteoclasts via a dose-dependent suppression of the M-CSF/RANK-ligand. In addition, in rats inoculated with the Adiponectin-Adenovirus (Adiponectin-LacZ), adiponectin reduced osteoclastogenesis and increased trabecular BND. It is therefore possible that this hormone may have an active role in attenuating bone loss after bariatric surgery, although further research in human subjects is needed to clarify its exact role. It is of note that osteocalcin, a hormone produced by osteoblasts, upregulates adiponectin in rodents 76 and humans, 77 thus supporting the notion that there is bidirectional feedback between bone metabolism and energy metabolism. Interestingly, adiponectin was shown to increase after RNYGB. 19, 78, 79 Serotonin Serotonin is produced in both the gastrointestinal and central nervous systems. In the duodenum, enterochromaffin cells respond to mechanical stress by producing tryptophan hydroxylase 1, the rate-limiting catalyst of gut-derived serotonin (GDS) production. 80 Approximately 95% of gut-derived serotonin is rapidly taken up by platelets and stored in granules that can be released in response to vascular injury. The remaining 5% is free in the serum and acts as a hormone to affect multiple metabolic 
Abbreviations: BMC, bone mineral content; BMD, bone mineral density; N, normal; NC, no changes; PTH, parathyroid hormone; m, increase; k, decrease.
processes, including gut motility and bone metabolism. GDS inhibits bone formation by binding and activating the ostoeblastic Htr1B receptor. 81 Serotonin that originates in the brain (BDS) is produced by the raphe nuclei, with tryptophan hydroxylase 2 as the rate-limiting enzyme. BDS has numerous central nervous system functions including the modulation of behavioral and emotional status and the mediation of leptin actions in the ventral medial hypothalamus. 82 It acts through the hypothalamic Htr2c receptor to inhibit sympathetic nervous tone. In response to increments in leptin mass or sensitivity, the BDS levels drop with consequent increase in sympathetic tone, inhibition of bone formation via activation of the osteoblastic Adr2b receptor and stimulation of bone resorption through the RANK-L system. 67 Knockout of the tryptophan hydroxylase 1 and 2 genes has demonstrated that GDS is a potent inhibitor of bone formation in the mouse, although BDS acts as promoter of osteogenesis; double gene knockout with consequent inhibition of both GDS and BDS results in a low bone mass phenotype. Following bariatric surgery and restoration of leptin sensitivity, one would expect an increment in BDS production, a hormonal response consistent with the bone loss experienced after this type of surgical intervention.
Glucose-dependent insulinotropic polypeptide GIP/gastric inhibitory polypeptide is a 42 amino-acid polypeptide initially isolated from porcine intestine in 1969. Initially, it was considered an inhibitor of gastric acid secretion, 83, 84 but later studies demonstrated glucose-dependent stimulation of insulin secretion by GIP, suggesting an incretin role. 85 In time, the term GIP became synonymous with glucose inhibitory polypeptide. GIP is released in response to oral nutrient ingestion from K-cells in the gut. [86] [87] [88] Its primary stimuli are fat and carbohydrates reaching the duodenum after meal ingestion. 89 The presence of nutrients in the duodenum must be coupled with nutrient absorption to trigger GIP secretion. 90 Further, such secretion is reduced in patients with intestinal malabsorption. 91 More recently, membrane receptors for GIP were identified in osteoblasts, osteocytes and osteoclasts, 92, 93 and GIP was shown to increase bone-specific alkaline phosphatase activity and to promote bone turnover both in vitro and in vivo. 93 Further, GIP inhibits osteoclast differentiation, resulting in decreased resorption. 94 Fasting and postprandial GIP levels were found to be reduced after RYGB. 95 In one study GIP levels were found to be reduced after RYGB but only in diabetic patients. 95 Ghrelin Ghrelin is a growth hormone-releasing peptide synthesized primarily in the stomach. In humans and other species ghrelin is a powerful stimulant of hunger and food intake. 96 Osteoblasts respond to gherlin with increased proliferation and differentiation. 97 Furthermore, ghrelin was shown to increase BND in rodents independent of growth hormone signaling. 92, 98 There is uncertainty as to the impact of various bariatric surgery procedures on ghrelin levels. The available studies are limited by their small cohort size. Postoperative decrease in ghrelin levels was reported exclusively when the fundus of the stomach was isolated or removed (RYGB and gastric sleeve). 99 Peptide YY PYY belongs to a polypeptide family that also includes neuropeptide Y and pancreatic polypeptide. It is secreted by small intestine and colonic L cells in response to food intake. 96 Low bone mass was observed in PYY gene knockout models. 100 PYY levels increase after RNYGB and biliopancreatic diversion, 101 adjustable gastric band, 102 and sleeve gastrectomy. 103 To our knowledge, no clinical study to date has correlated PYY levels with bone density in bariatric surgery patients.
Glucagon-like peptides (GLP-1, GLP-2)
The peptides GLP-1 and GLP-2, like PYY, are secreted by intestinal L cells in response to food intake. 93 GLP-1 is a glucose-dependent incretin hormone. An abrupt increase in GLP-1 levels after RNYGB is considered by many to be an important reason for rapid resolution of Type II diabetes in postoperative patients. [104] [105] [106] Exogenous administration of GLP-1 was shown to improve BND. 107 In addition, knockout of the GLP-1 receptor gene was shown to result in increased osteoclast number and activity in mice. Injection of GLP-2 into postmenopausal women decreased the circulating markers of bone resorption, but not of bone formation. 108 A rapid postprandial reduction in makers of bone resorption is also known to occur in men, which may result from secretion of any of a number of gut hormones. However, patients with short-bowel syndrome do not secrete GLP-2 or display reduced bone resorption in response to food intake. 109 In any case, rapid postprandial drop in bone resorption is of questionable clinical significance since a 2-year study of short-bowel syndrome patients did not demonstrate the reduction in BMD that one would expect if bone resorption were to increase in the absence of GLP-2. 110 One would expect low postprandial levels of GLP-2 after surgical removal of portions of the small intestine, although we were unable to identify any studies that specifically addressed this possibility.
Gonadal hormones Adipose tissue is the primary source of estrogen in men and postmenopausal women. 111 Under the control of the enzyme aromatase, testosterone is converted to estradiol in adipose tissue. Estrogen acts through a variety of mechanisms to suppress bone resorption and increase bone formation. 64, 112 As weight decreases and adipose stores are depleted, the levels of estrogen decrease in both men and women resulting in decreased impact of estrogen on bone. Estrogen may also affect bone metabolism by direct effects on vitamin D and calcium metabolism.
113,90
PROPOSED RESEARCH AGENDA A major limiting factor in the clinical application of the research referenced herein is the fact that the majority of the research has been performed in rodents and not in humans. Therefore, translational human research is a key step in identifying clinically relevant opportunities to attenuate the impact of bariatric surgery on bone health.
A second limiting factor is the short duration of most studies that assess bone turnover following bariatric surgery. When, combined with the explosion of bariatric procedures in the last 15 years, this raises the concern that the prevalence of fractures secondary to bariatric surgery may begin to accelerate in the next few years. A national registry for bariatric surgery outcomes known as the Bariatric Outcomes Longitudinal Database does not capture bone fractures as an adverse event, unless the patient's surgeon captures this as an 'other' adverse event.
A research agenda designed to collate a large cohort of bariatric surgery patients that includes all operative procedures is needed to fully elucidate the mechanisms involved in bone loss after bariatric surgery. It should evaluate changes in bone turnover markers, BND, gut hormones, markers of mechanostat function, nutrition and activity levels. Further, fracture rates must be monitored in this same cohort to determine if the bone loss is merely a reflection of 'normal' physiologic responses to reduced weight bearing or if it actually portends a higher risk of bony fractures.
